Conflict of Interest in Medical Research

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11220%2F23%3A10478042" target="_blank" >RIV/00216208:11220/23:10478042 - isvavai.cz</a>

Výsledek na webu

<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=FrJwKfya5I" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=FrJwKfya5I</a>

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Conflict of Interest in Medical Research

Popis výsledku v původním jazyce

Conflicts of interest in medical research have been regulated in many countries by various laws, policies or internal regulations, in order to enhance the quality of research and ethical standards of research integrity. Leaving aside the conflicts of interest of public officers (i.e., employees of regulatory bodies or main public research funds, etc.), the focus of this paper lies in mapping the US, EU and Czech legal frameworks, policies and practice designed to identify and further manage conflicts of interest of researchers conducting clinical trials, both from the perspective of regulatory/scientific bodies involved in authorizing the marketing application (namely, FDA, EMA and the Czech State Institute for Drug Control) and main public research funds (namely, National Institutes of Health, European Scientific Council and Czech Science Foundation and Technology Agency of the Czech Republic). As there has only been limited attention paid to conflicts of interest in research in the Czech Republic, the primary aim of this paper is to introduce the concept of conflicts of interest, together with some selected strategies for identifying and managing them, and to evaluate the current Czech approach towards conflicts of interest in medical research.

Název v anglickém jazyce

Conflict of Interest in Medical Research

Popis výsledku anglicky

Conflicts of interest in medical research have been regulated in many countries by various laws, policies or internal regulations, in order to enhance the quality of research and ethical standards of research integrity. Leaving aside the conflicts of interest of public officers (i.e., employees of regulatory bodies or main public research funds, etc.), the focus of this paper lies in mapping the US, EU and Czech legal frameworks, policies and practice designed to identify and further manage conflicts of interest of researchers conducting clinical trials, both from the perspective of regulatory/scientific bodies involved in authorizing the marketing application (namely, FDA, EMA and the Czech State Institute for Drug Control) and main public research funds (namely, National Institutes of Health, European Scientific Council and Czech Science Foundation and Technology Agency of the Czech Republic). As there has only been limited attention paid to conflicts of interest in research in the Czech Republic, the primary aim of this paper is to introduce the concept of conflicts of interest, together with some selected strategies for identifying and managing them, and to evaluate the current Czech approach towards conflicts of interest in medical research.

Druh

J_SC - Článek v periodiku v databázi SCOPUS

CEP obor

—

OECD FORD obor

50501 - Law

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2023

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Czech Yearbook of Public and Private International Law

ISSN

1805-0565

e-ISSN

1805-0999

Svazek periodika

2023

Číslo periodika v rámci svazku

14

Stát vydavatele periodika

CZ - Česká republika

Počet stran výsledku

20

Strana od-do

373-392

Kód UT WoS článku

—

EID výsledku v databázi Scopus

2-s2.0-85185676383